Congenital adrenal hyperplasia pathophysiology

Jump to: navigation, search

Congenital adrenal hyperplasia Microchapters


Patient Info


Historical Perspective



Epidemiology and Demographics

Risk Factors



Differentiating Congenital Adrenal Hyperplasia from other Diseases

Natural History, Complications and Prognosis


History and Symptoms

Physical Examination

Laboratory Findings


Chest X Ray



Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies


Medical Therapy


Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Congenital adrenal hyperplasia pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides


American Roentgen Ray Society Images of Congenital adrenal hyperplasia pathophysiology

All Images
Echo & Ultrasound
CT Images

Ongoing Trials at Clinical

US National Guidelines Clearinghouse

NICE Guidance

FDA on Congenital adrenal hyperplasia pathophysiology

CDC on Congenital adrenal hyperplasia pathophysiology

Congenital adrenal hyperplasia pathophysiology in the news

Blogs on Congenital adrenal hyperplasia pathophysiology</small>

Directions to Hospitals Treating Congenital adrenal hyperplasia

Risk calculators and risk factors for Congenital adrenal hyperplasia pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]



  • Simple Virilizing Form
    • Female fetuses demonstrate evidence of androgen excess including genital ambiguity. Precocious puberty, accelerated growth followed by premature growth arrest due to epiphiseal fusion can be noted. Because virilization or androgen excess can be very mild, it can be overlooked until later in life.
  • Salt-Wasting Form
    • These patients may have virilizing features but 2/3 will also manifest mineralocorticoid deficiency with salt wasting, hyperkalemia, and hypotension, usually within the first 2 weeks of life.
  • Nonclassical Form
    • Patients may present with amenorrhea/oligomenorrhea with signs of androgen excess such as hirsutism. These women usually present around puberty and resemble patients with polycystic ovarian syndrome.


All involved genes are autosomal. See the table under 'Biochemistry' subheading for chromosomal locations.

Because they code for enzymes with amplifiable activity, noticeable effects only occur in people with two defective alleles of thesegenes. Hundreds of different allelic mutations of these genes have been reported. Nearly always, each parent of an affected person is an unaffected heterozygote (i.e., asymptomatic carrier of one defective gene and one normal gene and has no ill effects). Each child of that pair of parents has a 25% chance of being affected, "having CAH". Prenatal diagnosis and heterozygote detection are now possible.

Although mutations leading to the various forms of CAH have been found all over the world, there are substantial differences in the carrier rates of specific abnormal alleles in different regions and ethnic groups.